Trials / Active Not Recruiting
Active Not RecruitingNCT05972473
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
A Phase 3, Randomized, Double-masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular Degeneration
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept Ophthalmic | 2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W). |
| BIOLOGICAL | IBI302 | 8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol. |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2027-02-28
- Completion
- 2027-04-30
- First posted
- 2023-08-02
- Last updated
- 2025-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05972473. Inclusion in this directory is not an endorsement.